Antiviral - CMV and/or HSV infection coverage

The phrase "Antiviral - CMV and/or HSV infection coverage" does not designate a formalized, standard pharmacologic class within major regulatory systems such as the FDA, but rather functions as a practical or administrative grouping for antiherpesviral agents Clinically, they provide targeted coverage for treating and preventing herpes simplex virus manifestations, including mucocutaneous lesions and encephalitis, as well as cytomegalovirus viremia and end-organ disease in vulnerable populations...

The phrase "Antiviral - CMV and/or HSV infection coverage" does not designate a formalized, standard pharmacologic class within major regulatory systems such as the FDA, but rather functions as a practical or administrative grouping for antiherpesviral agents These medications—primarily nucleoside and nucleotide analogues (e.g., acyclovir, valganciclovir, cidofovir) and non-nucleoside inhibitors like foscarnet or letermovir—act principally by inhibiting viral DNA polymerase or viral terminase co...

These medications—primarily nucleoside and nucleotide analogues (e.g., acyclovir, valganciclovir, cidofovir) and non-nucleoside inhibitors like foscarnet or letermovir—act principally by inhibiting viral DNA polymerase or viral terminase complexes to halt DNA replication

Clinically, they provide targeted coverage for treating and preventing herpes simplex virus manifestations, including mucocutaneous lesions and encephalitis, as well as cytomegalovirus viremia and end-organ disease in vulnerable populations such as solid organ or hematopoietic stem cell transplant recipients

Clinically, they provide targeted coverage for treating and preventing herpes simplex virus manifestations, including mucocutaneous lesions and encephalitis, as well as cytomegalovirus viremia and end-organ disease in vulnerable populations such as solid organ or hematopoietic stem cell transplant recipients